InTANK

InTANK Therapeutics is a preclinical-stage biotechnology company focused on developing next-generation cancer immunotherapies. The company's proprietary platform, InTANK (In-Tumor Activation of NK cells), is designed to overcome the immunosuppressive tumor microenvironment by locally activating Natural Killer (NK) cells directly within the tumor. This approach aims to enhance the efficacy of cell therapies against solid tumors while minimizing systemic toxicities. InTANK's pipeline primarily targets various solid tumor indications where traditional systemic immunotherapies have shown limited success. The company is a spin-out from the Dana-Farber Cancer Institute and leverages cutting-edge research in NK cell biology.